Citations

Mayo Clinic

Showing 10 of 108599 citations.

Hereditary myopathies with early respiratory insufficiency in adults
Naddaf, Elie , Milone, Margherita , Naddaf, Elie

Muscle & Nerve | February 9, 2017 | Volume: 56 | Issue: 5 | Pages: 881-886

10.1002/mus.25602 | PMID 28181274 Get It

ABSTRACTIntroduction: Hereditary myopathies with early respiratory insufficiency as a predominant feature of the clinical phenotype are uncommon and underestimated in adults. Methods: We reviewed the clinical and laboratory data of patients with hereditary myopathies who demonstrated early respiratory insufficiency before the need for ambulatory assistance. Only patients with disease‐causing mutations or a specific histopathological diagnosis were included. Patients with cardiomyopathy were excluded. Results: We identified 22 patients; half had isolated respiratory symptoms at onset. The diagnosis of the myopathy was often delayed, resulting in delayed ventilatory support. The most common myopathies were adult‐onset Pompe disease, myofibrillar myopathy, multi‐minicore disease, and myotonic dystrophy type 1. Single cases of laminopathy, MELAS (mitochondrial encephalomyopathy with lactic acidosis and strokelike events), centronuclear myopathy, and cytoplasmic body myopathy were identified. Conclusion: We highlighted the most common hereditary myopathies associated with early respiratory insufficiency as the predominant clinical feature, and underscored the importance of a timely diagnosis for patient care. Muscle Nerve 56: 881–886, 2017
Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods
Kransdorf, E. , Loghmanpour, Natasha A., Kanwar, Manreet , Temkit, M’hamed , Stehlik, Josef , Kransdorf, Evan P , Temkit, M'hamed H, Kanwar, Manreet K

Clinical Transplantation | February 9, 2017 | Volume: 31 | Issue: 4 | Pages: No page available

10.1111/ctr.12925 | PMID 28181298 Get It

AbstractBackgroundCardiac allograft vasculopathy (CAV) remains an important cause of graft failure after heart transplantation (HT). Although many risk factors for CAV have been identified, there are no clinical prediction models that enable clinicians to determine each recipient's risk of CAV.MethodsWe studied a cohort of 14 328 heart transplant recipients whose data were reported to the International Society for Heart and Lung Transplantation Registry between 2000 and 2010. The cohort was divided into training (75%) and test (25%) sets. Multivariable modeling was performed in the test set using variables available at the time of heart transplant using three methods: (i) stepwise Cox proportional hazard, (ii) regularized Cox proportional hazard, and (iii) Bayesian network.ResultsCardiac allograft vasculopathy developed in 4259 recipients (29.7%) at a median time of 3.0 years after HT. The regularized Cox proportional hazard model yielded the optimal performance and was also the most parsimonious. We deployed this model as an Internet‐based risk calculator application.ConclusionsWe have developed a clinical prediction model for assessing a recipient's risk of CAV using variables available at the time of HT. Application of this model may allow clinicians to determine which recipients will benefit from interventions to reduce the risk of development and progression of CAV.
Comparison of two double red cell collection settings on Fenwal Alyx apheresis instrument
Burgstaler, Edwin A. , Duffy, Kimberly J., Gandhi, Manish J.

Journal of Clinical Apheresis | February 9, 2017 | Volume: 32 | Issue: 6 | Pages: 392-396

10.1002/jca.21527 | PMID 28181293 Get It

AbstractThe Fenwal Alyx for collecting double red cell products has two red cell volume collection settings: fixed collection target of 360 ml (180 ml/unit) and a variable target of collecting either 400 or 360 ml (200 or 180 ml/unit), where the machine aims for the higher possible collection target. We retrospectively compared the two collection targets for the RBC content, donor time, technician time, and collection efficiency. We compared 18 fixed (F) target collections to 40 variable (V) target collections. All collections were performed as per the manufacturer's recommendations on Alyx and donors met the manufacturer's eligibility criteria. There was no significant difference in average whole blood processed (F: 963 ml, V: 1,000 ml); donor time (F: 43 min, V: 45 min) or technician time (F: 64 min, V: 64 min). There was a significant difference in unit volume (F: 283 ml, V: 300 ml); grams Hb/unit (F: 53 g, V: 57 g); ml RBC/unit (F: 157 ml, V: 167 ml); and RBC recovery (F: 87.8%, V: 88.9%). The fixed target had a significantly lower frequency of products with ≥51 g Hb (80.6%) than variable target (96.3%) and ≥153 ml RBC/unit (F: 55.6%, V: 96.3%). In conclusion, the variable target efficiently allows collections of products with higher red cell volume and hemoglobin without a significant increase in collection and processing time.
Case-based review: primary central nervous system lymphoma
Korfel, Agnieszka, Schlegel, Uwe, Hirose, Takanori , Johnson, Derek R. , Kaufmann, Timothy J. , Giannini, Caterina

Neuro-Oncology Practice | February 9, 2017 | Volume: 4 | Issue: 1 | Pages: 46-59

10.1093/nop/npw033 | PMID 31386044 Get It

AbstractPrimary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity. Ongoing trials are addressing issues such as the roles of reduced-dose radiotherapy, the addition of the CD20 antibody rituximab to chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation, and maintenance therapy in the primary management of PCNSL.
Sebaceous carcinoma in solid organ transplant recipients
Hoss, Elika, Nelson, Steven A. , Sharma, Amit

International Journal of Dermatology | February 9, 2017 | Volume: 56 | Issue: 7 | Pages: 746-749

10.1111/ijd.13490 | PMID 28181233 Get It

AbstractBackgroundThough a rare tumor, sebaceous carcinoma is relatively well‐described in immunocompetent patients, in whom it often occurs in a periorbital distribution where it has an overall poor prognosis with a high metastasis rate. The effect of transplant‐related immunosuppression on the development of sebaceous carcinoma and its outcomes has not been characterized.MethodsWe collected 9 cases from a single institution of patients developing sebaceous carcinoma after solid organ transplantation. We analyzed clinicopathologic features.ResultsWe estimate the prevalence of sebaceous carcinoma post‐solid organ transplantation to be 0.09%. The mean age at diagnosis was 66.1 years (std 7.0 years). The mean time between transplantation and sebaceous carcinoma diagnosis was 7.1 years (std 5.1 years). All tumors occurred in extra‐ocular distribution. Two patients likely had Muir‐Torre syndrome, of whom 1 died from metastatic sebaceous carcinoma. No other patients developed metastatic disease or had disease‐related death. Mohs micrographic surgery and wide local excision were equally effective and there were no recurrences with either procedure.ConclusionsOur study found that sebaceous carcinoma in solid organ transplant recipients occurs in in an extraorbital distribution with only 1 patient developing metastatic disease. Both Mohs micrographic surgery and wide local excision are acceptable treatment modalities for sebaceous carcinoma in transplant recipients.
Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions
Pollock, Kathryn, Samsonraj, Rebekah M. , Dudakovic, Amel , Thaler, Roman , Stumbras, Aron R., McKenna, David H. , Dosa, Peter I. , Wijnen, André J. van , Hubel, Allison , van Wijnen, Andre J, van Wijnen, Andre J

Stem Cells and Development | February 9, 2017 | Volume: 26 | Issue: 11 | Pages: 828-842

10.1089/scd.2016.0347 | PMID 28178884 Get It

Magnesium Presence Prevents Removal of Antigenic Nuclear-Associated Proteins from Bovine Pericardium for Heart Valve Engineering
Dalgliesh, Ailsa J. , Liu, Zhi Zhao, Griffiths, Leigh G. , Griffiths, Leigh G

Tissue Engineering Part A | February 9, 2017 | Volume: 23 | Issue: 13-14 | Pages: 609-621

10.1089/ten.tea.2016.0405 | PMID 28178887 Get It

Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta‐regression analysis
Mainou, Maria , Madenidou, Anastasia‐Vasiliki , Liakos, Aris , Paschos, Paschalis , Karagiannis, Thomas , Bekiari, Eleni , Vlachaki, Efthymia , Murad, M. Hassan , Kumar, Shaji , Τσάπας, Απόστολος , Murad, Mohammad Hassan, Wang, Zhen , Liakos, A , Tsapas, A , Murad, M Hassan , Karagiannis, Thomas , Bekiari, Eleni

European Journal of Haematology | February 8, 2017 | Volume: 98 | Issue: 6 | Pages: 563-568

10.1111/ejh.12868 | PMID 28178364 Get It

AbstractObjectivesWe performed a systematic review and meta‐regression analysis of randomized control trials to investigate the association between response to initial treatment and survival outcomes in patients with newly diagnosed multiple myeloma (MM).MethodsResponse outcomes included complete response (CR) and the combined outcome of CR or very good partial response (VGPR), while survival outcomes were overall survival (OS) and progression‐free survival (PFS). We used random‐effect meta‐regression models and conducted sensitivity analyses based on definition of CR and study quality.ResultsSeventy‐two trials were included in the systematic review, 63 of which contributed data in meta‐regression analyses. There was no association between OS and CR in patients without autologous stem cell transplant (ASCT) (regression coefficient: .02, 95% confidence interval [CI] −0.06, 0.10), in patients undergoing ASCT (−.11, 95% CI −0.44, 0.22) and in trials comparing ASCT with non‐ASCT patients (.04, 95% CI −0.29, 0.38). Similarly, OS did not correlate with the combined metric of CR or VGPR, and no association was evident between response outcomes and PFS. Sensitivity analyses yielded similar results.ConclusionsThis meta‐regression analysis suggests that there is no association between conventional response outcomes and survival in patients with newly diagnosed MM.
Sarcoidosis Increases Risk of Hospitalized Infection. A Population-based Study, 1976–2013
Ungprasert, Patompong , Crowson, Cynthia S. , Matteson, Eric L.

Annals of the American Thoracic Society | February 8, 2017 | Volume: 14 | Issue: 5 | Pages: 676-681

10.1513/annalsats.201610-750oc | PMID 28177656 Get It

Abstract Rationale Patients with sarcoidosis may have an increased risk of infection similar to other immune-mediated disorders. However, the data are still limited. Objectives To investigate the risk of hospitalized infection among patients with sarcoidosis, using a population-based cohort. Methods Using the Rochester Epidemiology Project record-linkage system, a cohort of incident cases of sarcoidosis in Olmsted County, Minnesota from 1976 to 2013 was identified. Diagnosis was confirmed by individual medical record review. For each patient with sarcoidosis, a sex- and age-matched comparator without sarcoidosis was randomly selected from the same population. Medical records of cases and comparators were individually reviewed for hospitalized infection that occurred after the index date. The cumulative incidence of hospitalized infection overall and by type of infection, adjusted for the competing risk of death, was estimated. Cox models were used to compare the rate of first hospitalized infection between cases and comparators and to evaluate the association between use of immunosuppressive agents and hospitalized infection among cases. Results Three hundred and forty-five cases and 345 comparators were identified. Patients with sarcoidosis had a higher risk of a hospitalized infection with a hazard ratio (HR) of 2.00 (95% confidence interval [CI], 1.41–2.84), adjusted for age, sex, and calendar year of index date. Use of oral glucocorticoids was a significant predictor of hospitalized infection with an HR of 3.03 (95% CI, 1.33–6.90) for oral glucocorticoids not exceeding 10 mg/day and an HR of 4.48 (95% CI, 1.54–13.03) for oral glucocorticoids greater than 10 mg/day. Conclusions Patients with sarcoidosis are at increased risk of hospitalized infection. Glucocorticoid therapy is strongly associated with this increased risk.